Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Novel method of minimal residual disease testing in myeloma: Liquid biopsies to enumerate and 3D telomere-profiling of circulating tumor cells

View Full Paper
Ask AI
Bookmark
Share

Authors

YSYulia ShifrinJKJack KhouriCSChristy Samaras

Discussion

Loading...

Member takes

Overview

This analysis combines liquid biopsies and 3D telomere profiling to assess minimal residual disease in myeloma patients, indicating potential for improved monitoring and treatment response.

Key Points

  • Liquid biopsies enable continuous monitoring of minimal residual disease without invasive bone marrow aspiration.
  • High sensitivity was achieved in detecting circulating tumor cells across various disease stages.
  • Immunophenotyping and 3D telomere profiling provide insights into genomic instability and disease progression.
  • The method allows for actionable data on residual multiple myeloma cells, enhancing treatment strategies.

Cite This Study

Shifrin et al. (2025) studied this question.

synapsesocial.com/papers/69362f4b4fa91c937236d7dfhttps://doi.org/10.1182/blood-2025-2217
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Liquid biopsy for non-invasive molecular characterization and measurable residual disease analysis in multiple myeloma2025
  2. 2Peripheral circulating myeloma cells accurately identify bone marrow MRD positivity in multiple myeloma patients receiving CAR T or autologous transplant2025
  3. 3Pilot study of cell-free DNA (cfDNA) for measurable residual disease monitoring following autologous hematopoietic cell transplant in multiple myeloma2025 · 2 citations
  4. 4Minimally invasive characterization of peripheral blood measurable residual disease in multiple myeloma using high‐sensitivity detection of ctDNA by next‐generation sequencing2026 · 1 citations
  5. 5Three-Dimensional Organization of Telomeres: An Emerging Prognostic Biomarker in Multiple Myeloma2025